Laboratory Products and Outsourcing Services Market Report 2026

The laboratory products and outsourcing services market size has grown rapidly in recent years. It will grow from $45.81 billion in 2025 to $50.95 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to expansion of pharmaceutical and biotech research activity, growth in clinical trial volumes, increasing complexity of regulatory requirements, rising demand for specialized laboratory testing, availability of contract research services.

The laboratory products and outsourcing services market size is expected to see rapid growth in the next few years. It will grow to $77.15 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to increasing demand for end-to-end laboratory outsourcing, rising adoption of digital lab management platforms, expansion of personalized medicine research, growing focus on data integrity and compliance, increasing investments in advanced laboratory automation. Major trends in the forecast period include increasing outsourcing of laboratory testing services, rising demand for advanced analytical instruments, growing adoption of automated laboratory workflows, expansion of bioanalytical and stability testing services, enhanced focus on regulatory compliance support.

The increasing adoption of personalized medicine is expected to drive the growth of the laboratory products and outsourcing services market going forward. Personalized medicine refers to a medical approach that tailors healthcare decisions and treatments according to an individual’s genetic makeup, lifestyle, and environmental factors. The expansion of personalized medicine is fueled by rising demand for more effective and targeted therapies that reduce side effects and enhance patient outcomes. Laboratory products and outsourcing services support personalized medicine by facilitating high-throughput genetic testing, biomarker analysis, and specialized diagnostic services that are critical for customizing treatments for individual patients. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the FDA approved 16 new personalized treatments in 2023, an increase from six approvals in 2022. Personalized medicines represented more than one-third of all new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year. Therefore, the growing adoption of personalized medicine is contributing to the expansion of the laboratory products and outsourcing services market.

Major companies operating in the laboratory products and outsourcing services market are concentrating on developing advanced solutions such as integrated development and manufacturing platforms to provide end-to-end services, lower operational complexity, and enhance scalability for clients. An integrated development and manufacturing platform is defined as a consolidated system that brings together research, development, analytical testing, and manufacturing activities within a single streamlined framework to improve coordination, shorten timelines, and increase overall efficiency in biopharmaceutical production. For example, in March 2025, Shilpa Medicare Ltd., an India-based pharmaceutical company, introduced a new full-service hybrid contract development and manufacturing organization (CDMO) to deliver integrated solutions spanning early development through commercial manufacturing. The platform offers both flexible outsourcing through traditional CDMO services and ready-to-license novel formulations, supporting faster and lower-risk market entry for pharmaceutical companies. The objective is to provide multiple commercialization pathways, enabling either development support projects or rapid B2B licensing, particularly in oncology and complex therapeutics.

In August 2024, Biopharma Technology LLC, a US-based provider of versatile contract development and manufacturing organization (CDMO) services, entered into a partnership with Arete Biosciences LLC to establish a dedicated research and development analysis facility. This collaboration is intended to launch a small-batch manufacturing laboratory in the United States to deliver comprehensive contract development and manufacturing organization (CDMO) services and enhance accessibility for U.S.-based biopharmaceutical and diagnostics companies. Arete Biosciences LLC is a US-based company that offers laboratory outsourcing services through integrated contract development and manufacturing organization (CDMO) service solutions.

Major companies operating in the laboratory products and outsourcing services market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, IQVIA Holdings Inc., Labcorp Holdings Inc., Quest Diagnostics, SGS SA, Eurofins Scientific Inc., Agilent Technologies Inc., WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., Intertek Group plc., Waters Corporation, Bio-Rad Laboratories Inc., ALS Limited, PerkinElmer Inc., Medpace Holdings Inc., Tecan Group AG, Greiner Bio-One International GmbH, Randox Laboratories Ltd., Tulip Diagnostics Private Limited.

North America was the largest region in the laboratory products and outsourcing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the laboratory products and outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the laboratory products and outsourcing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the laboratory products and outsourcing services market by increasing costs of imported analytical instruments, reagents, consumables, and specialized laboratory equipment. Pharmaceutical and biotech companies in North America and Europe are most affected due to dependence on imported lab technologies, while Asia-Pacific faces pricing pressure on instrument manufacturing. These tariffs are increasing operational costs and project budgets for laboratory service providers. However, they are also encouraging local instrument production, regional reagent manufacturing, and expansion of domestic laboratory service capabilities.

The laboratory products and outsourcing services market research report is one of a series of new reports that provides laboratory products and outsourcing services market statistics, including laboratory products and outsourcing services industry global market size, regional shares, competitors with a laboratory products and outsourcing services market share, detailed laboratory products and outsourcing services market segments, market trends and opportunities, and any further data you may need to thrive in the laboratory products and outsourcing services industry. This laboratory products and outsourcing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Laboratory products and outsourcing services refer to a combination of tools, instruments, and consumables used in scientific and diagnostic laboratories, along with external services that assist laboratory operations. This includes a wide range of offerings, from analytical instruments and reagents to outsourced research, testing, and diagnostic services.

The primary types of laboratory products and outsourcing services include products, services, method development and validation, stability testing, and others. Products comprise physical items such as instruments, reagents, consumables, and analytical tools used in scientific and industrial research. The spectrum of technologies covers immunoassays, molecular diagnostics, microbiology, clinical chemistry, flow cytometry, mass spectroscopy, chromatography, and others. These offerings are used by end users such as pharmaceutical and biotechnology companies, medical device manufacturers, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and others.

The laboratory products and outsourcing services market consists of revenues earned by entities by providing services such as analytical testing services, bioanalytical services, and sample management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The laboratory products and outsourcing services market also includes sales of analytical instruments, life sciences equipment, and general lab equipment. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.